BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort. METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu). RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe. DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.

161st Division of Internal Medicine and Hepato Gastroenterology Unit University Hospital Ioannina Greece

Department of Gastroenterology Adelaide and Meath Hospital Trinity College of Dublin Dublin Ireland

Department of Gastroenterology and Alimentary Tract Surgery Tampere University Hospital Tampere Finland

Department of Gastroenterology and Hepatology Soroka Medical Center and Ben Gurion University of the Negev Beer Sheva Israel

Department of Medical Gastroenterology Odense University Hospital Odense Denmark

Department of Medicine 5 Aarhus University Hospital Arhus Denmark

Department of Medicine Amager Hospital Amager Denmark

Department of Medicine Csolnoky F Province Hospital Veszprem Hungary

Department of Medicine Herning Central Hospital Herning Denmark

Division of Endocrinology and Gastroenterology Tartu University Hospital Tartu Estonia

Division of Gastroenterology and Hepatology University Hospital Center Zagreb University of Zagreb School of Medicine Zagreb Croatia

EpiCom Northern Italy Centre based in Crema and Cremona Padova and Reggio Emilia Italy

Gastroenterology Department Hospital České Budějovice České Budějovice Czech Republic

IBD Center ISCARE Charles University Prague Czech Republic

Institute of Regional Health Research University of Southern Denmark Odense Denmark

Medical Department Dronning Ingrids Hospital Nuuk Greenland

Medical Department Hospital of Southern Jutland Aabenraa Denmark

Medical Department The National Hospital of the Faroe Islands Torshavn Faroe Islands

Medical Department Viborg Regional Hospital Viborg Denmark

Medical Section Digestive Disease Centre Medical Section Herlev University Hospital Copenhagen Denmark

Nicosia Private Practice Nicosia Cyprus

U O Gastroenterologia Azienda Ospedaliera Università di Padova Padova Italy

UO Medicina 3° e Gastroenterologia Azie

000      

00000naa a2200000 a 4500

001      

bmc14074498

003      

CZ-PrNML

005      

20161026135058.0

007      

ta

008      

141006s2014 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1097/01.MIB.0000436277.13917.c4 $2 doi

035    __

$a (PubMed)24252978

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Burisch, Johan $u 1Medical Section, Digestive Disease Centre, Medical Section, Herlev University Hospital, Copenhagen, Denmark; 2Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia; 3Nicosia Private Practice, Nicosia, Cyprus; 4IBD Center ISCARE, Charles University, Prague, Czech Republic; 5Gastroenterology Department, Hospital České Budějovice, České Budějovice, Czech Republic; 6Department of Medicine, Amager Hospital, Amager, Denmark; 7Department of Medicine, Herning Central Hospital, Herning, Denmark; 8Medical Department, Viborg Regional Hospital, Viborg, Denmark; 9Medical Department, Hospital of Southern Jutland, Aabenraa, Denmark; 10Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark; 11Department of Medicine V (Hepatology and Gastroenterology), Aarhus University Hospital, Arhus, Denmark; 12Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark; 13Division of Endocrinology and Gastroenterology, Tartu University Hospital, Tartu, Estonia; 14Medical Department, The National Hospital of the Faroe Islands, Torshavn, Faroe Islands; 15Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland; 161st Division of Internal Medicine and Hepato-Gastroenterology Unit, University Hospital, Ioannina, Greece; 17Medical Department, Dronning Ingrids Hospital, Nuuk, Greenland; 18Department of Medicine, Csolnoky F. Province Hospital, Veszprem, Hungary; 19Department of Gastroenterology, Adelaide and Meath Hospital, Trinity College of Dublin, Dublin, Ireland; 20Department of Gastroenterology and Hepatology, Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel; 21U.O. Gastroenterologia, Azienda Ospedaliera, Università di Padova, Padova, Italy; 22EpiCom Northern Italy Centre based in Crema & Cremona, Padova and Reggio Emilia, Italy; 23UO Medicina 3° e Gastroenterologia, Azie

245    10

$a Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort / $c J. Burisch, N. Pedersen, S. Cukovic-Cavka, N. Turk, I. Kaimakliotis, D. Duricova, O. Shonová, I. Vind, S. Avnstrøm, N. Thorsgaard, S. Krabbe, V. Andersen, F. Dahlerup Jens, J. Kjeldsen, R. Salupere, J. Olsen, KR. Nielsen, P. Manninen, P. Collin, KH. Katsanos, EV. Tsianos, K. Ladefoged, L. Lakatos, Y. Bailey, C. O'Morain, D. Schwartz, S. Odes, M. Martinato, S. Lombardini, L. Jonaitis, L. Kupcinskas, S. Turcan, L. Barros, F. Magro, D. Lazar, A. Goldis, I. Nikulina, E. Belousova, A. Fernandez, V. Hernandez, S. Almer, Y. Zhulina, J. Halfvarson, HH. Tsai, S. Sebastian, PL. Lakatos, E. Langholz, P. Munkholm, . ,

520    9_

$a BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort. METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu). RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe. DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.

650    _2

$a mladiství $7 D000293

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a kombinovaná terapie $7 D003131

650    12

$a databáze faktografické $7 D016208

650    _2

$a progrese nemoci $7 D018450

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a následné studie $7 D005500

650    _2

$a lidé $7 D006801

650    _2

$a incidence $7 D015994

650    _2

$a idiopatické střevní záněty $x epidemiologie $x terapie $7 D015212

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a prognóza $7 D011379

650    _2

$a prospektivní studie $7 D011446

650    _2

$a indukce remise $7 D012074

650    _2

$a mladý dospělý $7 D055815

651    _2

$a Evropa $x epidemiologie $7 D005060

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Pedersen, Natalia

700    1_

$a Cukovic-Cavka, Silvja

700    1_

$a Turk, Niksa

700    1_

$a Kaimakliotis, Ioannis

700    1_

$a Duricova, Dana

700    1_

$a Shonová, Olga

700    1_

$a Vind, Ida $7 xx0207519

700    1_

$a Avnstrøm, Søren $7 gn_A_00010378

700    1_

$a Thorsgaard, Niels

700    1_

$a Krabbe, Susanne

700    1_

$a Andersen, Vibeke $7 gn_A_00006098

700    1_

$a Dahlerup Jens, Frederik

700    1_

$a Kjeldsen, Jens

700    1_

$a Salupere, Riina

700    1_

$a Olsen, Jóngerð

700    1_

$a Nielsen, Kári Rubek

700    1_

$a Manninen, Pia

700    1_

$a Collin, Pekka

700    1_

$a Katsanos, Konstantinnos H

700    1_

$a Tsianos, Epameinondas V

700    1_

$a Ladefoged, Karin

700    1_

$a Lakatos, Laszlo

700    1_

$a Bailey, Yvonne

700    1_

$a O'Morain, Colm

700    1_

$a Schwartz, Doron

700    1_

$a Odes, Selwyn

700    1_

$a Martinato, Matteo

700    1_

$a Lombardini, Silvia

700    1_

$a Jonaitis, Laimas

700    1_

$a Kupcinskas, Limas

700    1_

$a Turcan, Svetlana

700    1_

$a Barros, Louisa

700    1_

$a Magro, Fernando

700    1_

$a Lazar, Daniela

700    1_

$a Goldis, Adrian

700    1_

$a Nikulina, Inna

700    1_

$a Belousova, Elena

700    1_

$a Fernandez, Alberto

700    1_

$a Hernandez, Vicent

700    1_

$a Almer, Sven $7 gn_A_00004635

700    1_

$a Zhulina, Yaroslava

700    1_

$a Halfvarson, Jonas

700    1_

$a Tsai, Her-Hsin

700    1_

$a Sebastian, Shaji

700    1_

$a Lakatos, Peter Laszlo

700    1_

$a Langholz, Ebbe

700    1_

$a Munkholm, Pia

700    1_

$a ,

773    0_

$w MED00002243 $t Inflammatory bowel diseases $x 1536-4844 $g Roč. 20, č. 1 (2014), s. 36-46

856    41

$u https://pubmed.ncbi.nlm.nih.gov/24252978 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20141006 $b ABA008

991    __

$a 20161026135513 $b ABA008

999    __

$a ok $b bmc $g 1042381 $s 873410

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2014 $b 20 $c 1 $d 36-46 $i 1536-4844 $m Inflammatory bowel diseases $n Inflamm Bowel Dis $x MED00002243

LZP    __

$a Pubmed-20141006